Use: Labeled indications
- Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
Contraindications
4 CONTRAINDICATIONS Meclizine hydrochloride is contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11)]. Meclizine hydrochloride is contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients.
US FDA labelDosing: Adult
Recommended dosage: 25 mg to 100 mg daily, in divided doses (2.1). Tablets: Swallow whole (2.2). Chewable Tablets: Must be chewed or crushed before swallowing; do not swallow whole (2.2).
2.1 Recommended Dosage
2.1 Recommended Dosage The recommended dosage is 25 mg to 100 mg daily administered orally, in divided doses, depending upon clinical response.
2.2 Administration Instructions Tablets
2.2 Administration Instructions Tablets Meclizine hydrochloride tablets must be swallowed whole. Chewable Tablets Meclizine hydrochloride chewable tablets must be chewed or crushed completely before swallowing. Do not swallow chewable tablets whole.
Dosing: Altered kidney function
8.7 Renal Impairment The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Because of a potential for drug/metabolite accumulation, meclizine hydrochloride should be administered with caution in patients with renal impairment and in the elderly, as renal function generally declines with age.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine hydrochloride undergoes metabolism, hepatic impairment may result in increased systemic exposure of meclizine. Treatment with meclizine hydrochloride should be administered with caution in patients with hepatic impairment.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Administration
2.2 Administration Instructions Tablets Meclizine hydrochloride tablets must be swallowed whole. Chewable Tablets Meclizine hydrochloride chewable tablets must be chewed or crushed completely before swallowing. Do not swallow chewable tablets whole.
US FDA labelDosage forms
Philippines
- Chewable tablet: 12.5 mg, 25 mg
- Tablet: 25 mg
Registered products in the Philippines
26 products registered with the Food and Drug Administration (FDA) Philippines list Meclizine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products26
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BonamineMeclizine Hydrochloride | 12.5 mg Chewable TabletAlu/PVC Blister Pack x 10's and 30's (Box of 120's) | OTC | Interphil Laboratories, Inc.Philippines | Trader: Taisho Pharmaceuticals (Philippines), Inc. | DR-XY19867 | Oct 21, 2029 | |
BonamineMeclizine Hydrochloride | 25 mg Chewable TabletAlu/PVC Blister pack x 10's (Box of 240's) | OTC | Interphil Laboratories, Inc.Philippines | Trader: Taisho Pharmaceuticals Philippines Inc. | DR-XY22028 | May 22, 2029 | |
BonazinMeclizine Hydrochloride | 12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-13361 | Feb 6, 2028 | |
Bonazin ForteMeclizine Hydrochloride | 25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-11990 | Jun 6, 2027 | |
EramelMeclizine Hydrochloride | 12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-13361-01 | Feb 6, 2028 | |
EramelMeclizine Hydrochloride | 25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-11990-01 | Jun 6, 2027 | |
MecligenMeclizine Hydrochloride | 12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: EBA Generisch Trading Inc. | DRP-13191 | Dec 22, 2027 | |
Mecligen ForteMeclizine Hydrochloride | 25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-13360 | Feb 6, 2028 | |
MeclineMeclizine Hydrochloride | 12.5 mg Chewable TabletClear PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker’s Laboratories Inc.Laguna | — | DR-XY46823 | Feb 4, 2032 | |
MeclitabMeclizine Hydrochloride | 12.5 mg Chewable TabletClear PVDC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: D.B. Manix International, Inc. | DRP-10048 | May 25, 2030 | |
MeclitabMeclizine Hydrochloride | 25 mg Chewable TabletClear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: D.B. Manix International, Inc. | DR-XY37989 | May 25, 2030 | |
MeclizanMeclizine Hydrochloride | 25mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-11990-03 | Jun 6, 2027 | |
MeclizsaphMeclizine Hydrochloride | 25 mg Chewable TabletAlu-clear/PVC Blister Pack x 10's (Box of 100's) | OTC | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-10228 | Aug 13, 2031 | |
MelzinMeclizine Hydrochloride | 25mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc. | DRP-11990-02 | Jun 6, 2027 | |
NoneMeclizine | 25 mg Chewable TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Vonwelt, Inc.Philippines | — | DR-XY42804 | Oct 11, 2030 | |
NoneMeclizine | 25 mg Chewable TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Vonwelt IncPhilippines | — | DRP-13537 | Oct 11, 2030 | |
NoneMeclizine Hydrochloride | 25 mg Chewable TabletBlister Strip x 10s Box of 100's | OTC | Am-Europharma CorporationPhilippines | Trader: RITEMED PHILS., INC. | DRP-8269 | Sep 19, 2029 | |
NoneMeclizine Hydrochloride | 25 mg Chewable TabletBlister Strip x 10's (Box of 100's) | Rx | Am-Europharma CorporationPhilippines | Trader: Ritemed Phils., Inc. | DRP-8638 | Jan 21, 2030 | |
NovomitMeclizine Hydrochloride | 12.5 mg Chewable tabletAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DR-XY47358 | Aug 16, 2036 | |
NovomitMeclizine Hydrochloride | 25 mg Chewable TabletAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DR-XY46605 | Jun 4, 2029 | |
RamecMeclizine Hydrochloride | 12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.,Philippines | Trader: St. Raphael Archạngel Pharmaceutical Product Distribution | DRP-11989 | May 26, 2027 | |
Ramec ForteMeclizine Hydrochloride | 25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.,Philippines | Trader: St. Raphael Archangel Pharmaceutical Product Distribution | DRP-11955 | Jun 6, 2027 | |
UnbrandedMeclizine Hydrochloride | 25 mg TabletAlu/PCDC/PVC Clear Blister pack x 10's (Box of 100's) | OTC | AM-EUROPHARMA CORPORATIONPhilippines | AM-EUROPHARMA CORPORATION | DRP-8280 | Oct 22, 2029 | |
United Home DizitabMeclizine Hydrochloride | 25 mg Chewable TabletBlister Strip x 10's (Box of 100's) | OTC | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY32470 | Oct 5, 2027 | |
(no brand name)Meclizine hydrochloride | 12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc,Philippines | — | DRP-14659 | Nov 17, 2028 | |
(no brand name)Meclizine hydrochloride | 12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: Daily Grace Unlimited, Inc. | DRP-14824 | Jan 17, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets 12.5 mg: oval-shaped, biconvex, two-layered tablet, one blue to pale blue layer debossed with “34” and one white to off white layer debossed with “L”. 25 mg: oval-shaped, biconvex, two-layered tablet, one yellow to pale yellow layer debossed with “49” and one white to off white layer debossed with “L”. 50 mg: oval-shaped, biconvex, two-layered tablet, one blue to pale blue layer debossed with “50” and one yellow to pale yellow layer and debossed with “L”. Chewable Tablets 25 mg: pink colored round tablets debossed with “M 25” on one side and break line on other side.
Tablets: 12.5 mg, 25 mg, and 50 mg (3). Chewable Tablets: 25 mg (3).
Warnings/Precautions
May cause drowsiness: Use caution when driving a car or operating dangerous machinery (5.1). Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland (5.2).
5.1 Drowsiness
5.1 Drowsiness Since drowsiness may occur with use of meclizine hydrochloride, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery. Patients should avoid alcoholic beverages while taking meclizine hydrochloride [see Drug Interactions (7.1)].
5.2 Concurrent Medical Conditions
5.2 Concurrent Medical Conditions Because of its potential anticholinergic action, meclizine hydrochloride should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.
Drug interactions
Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression (7.1). CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors (7.2).
7.1 CNS Depressants
7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride is administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1)].
7.2 CYP2D6 Inhibitors Based
7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.
CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). 7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride is administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1) ] . 7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6.
Therefore, there is a possibility for a drug interaction between meclizine hydrochloride and CYP2D6 inhibitors.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions associated with the use of meclizine hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported. Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported (6). To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. However, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Human Data Epidemiological studies reporting on pregnancies exposed to meclizine have not identified an association between the use of meclizine during pregnancy and an increased risk of major birth defects.
Animal Data In a published study, oral administration of meclizine (25-250 mg/kg) to pregnant rats during the period of organogenesis resulted in a high incidence of fetal malformations. These effects occurred at doses as low as 25 mg/kg, which is approximately 2 times the maximum recommended human dose (100 mg) on a body surface area (mg/m2) basis.
Mechanism of action
12.1 Mechanism of Action The precise mechanism by which meclizine exerts its therapeutic effect is unknown but is presumed to involve antagonism of the histamine H1 receptor.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics There are no relevant pharmacodynamic data regarding meclizine.
Pharmacokinetics
Elimination Meclizine has a plasma elimination half-life of about 5-6 hours in humans.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature. Absorption Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.
Distribution Drug distribution characteristics for meclizine in humans are unknown. Elimination Meclizine has a plasma elimination half-life of about 5-6 hours in humans. Metabolism In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Meclizine Hydrochloride · Rising Pharma Holdings, Inc. [US FDA-approved label, version 3, June 2, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .